Cargando…

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis

INTRODUCTION: Apremilast is the new oral drug in the management of moderate-to-severe plaque psoriasis with well-established effectiveness and safety in long-term clinical trials and a few real-world studies. However, its effectiveness and safety in Indian setup have not been reported yet. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Bela J., Mistry, Deval, Chaudhary, Navin, Shah, Shikha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001393/ https://www.ncbi.nlm.nih.gov/pubmed/32055509 http://dx.doi.org/10.4103/idoj.IDOJ_169_19

Ejemplares similares

Apremilast in People Living with HIV with Psoriasis Vulgaris: A Case Report
por: Shah, Bela J, et al.
Publicado: (2019)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan, Murlidhar, et al.
Publicado: (2021)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe
por: Cetkovská, Petra, et al.
Publicado: (2023)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
por: Reich, K., et al.
Publicado: (2018)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris
por: Morita, Akimichi, et al.
Publicado: (2022)

A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis
por: Srivastava, Divyanshu, et al.
Publicado: (2023)

Treatment of pyoderma gangrenosum with apremilast monotherapy
por: Bordeaux, Zachary A., et al.
Publicado: (2022)

Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
por: Jonak, Constanze, et al.
Publicado: (2023)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
por: Reich, K., et al.
Publicado: (2016)

A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
por: Haque, Emily K., et al.
Publicado: (2020)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study
por: MALARA, Giovanna, et al.
Publicado: (2021)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
por: Van Voorhees, A.S., et al.
Publicado: (2021)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
por: Klein, Toni Maria, et al.
Publicado: (2021)

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases
por: Marovt, Maruška, et al.
Publicado: (2021)

Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies
por: Liu, Yashu, et al.
Publicado: (2022)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study
por: de Vlam, Kurt, et al.
Publicado: (2022)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
por: Salopek, Thomas G.
Publicado: (2017)

Efficacy of Apremilast Gels in Mouse Model of Imiquimod-Induced Psoriasis Skin Inflammation
por: Silva-Abreu, Marcelle, et al.
Publicado: (2023)

Real‐world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety
por: Asawanonda, Pravit, et al.
Publicado: (2022)

Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study
por: Giofrè, Claudia, et al.
Publicado: (2023)

Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
por: Li, Gaojie, et al.
Publicado: (2022)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Recurrent generalized pustular psoriasis possibly triggered by apremilast
por: Wang, Wen-Ming, et al.
Publicado: (2020)

A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021)

Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus
por: Viswanath, Vishalakshi, et al.
Publicado: (2022)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
por: Siciliano, Maria Anna, et al.
Publicado: (2020)

Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study
por: Ghislain, Pierre-Dominique, et al.
Publicado: (2022)

Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study
por: Okubo, Yukari, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qcik6ss88r9nh8ncstj7npn0tc